We provide aggregated data on dividend stocks. AbbVie has been named a Top Socially ... Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being ...

This article provides an updated list of the Dividend Kings in 2025, select financial data and analysis. The list and data ...

Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...

AbbVie holds a strong portfolio of marketed and ... Imbruvica's strong clinical data in several forms of blood cancer led to peak sales above $5 billion, but increasing competition has led to ...

The information for this article is based on a press release statement and InvestingPro data, where investors can access a comprehensive Pro Research Report covering AbbVie's detailed financial ...

According to InvestingPro data, AbbVie maintains a strong financial position as a prominent player in the Biotechnology industry, with an EBITDA of $25.6 billion in the last twelve months.